The prevalence of abnormalities of lipoprotein cholesterol and apollpopratelns A-I and B and Ilpoproteln (a) [Lp(a)] was determlined In 321 men (mean age 50 ± 7 years) with aagiographicelly documented coronary artery disease and compared with that in 901 control subjects from the Framlngham (IBvpring Stud) (mean age 49 A 6 years) who were clinically free of coronary artery disease. After correction far sampling In hospital, hem-adrenerglc medication use and elects ofdiel,patientshad$gnlUnruly higher cholesterol levels (224 ± 53 vs . 214 ± 36 mgldl), triglycerides (189 ± 95 vs. 141 ± 104 mgld0, low density ipoprotee (LDL) cholesterol (156 t 51 vs . 138 3 33 mgldl), apolipoprote[n B (131 m 37 vs. 108 ± 33 agldl) and Lp(a) levels (19.9 *-t9 vs. 14.9 ± 17.5 mg/dl). They also had significantly lower high density lipoprotein (HDL) cholesterol (36 A 11 vs . 45 ± 12 mgldl) and apolipoprolein A-] levels (114 ± 26 vs . 136 4 32 mg'dl) (all p < 0.005).
The prevalence of abnormalities of lipoprotein cholesterol and apollpopratelns A-I and B and Ilpoproteln (a) [Lp(a)] was determlined In 321 men (mean age 50 ± 7 years) with aagiographicelly documented coronary artery disease and compared with that in 901 control subjects from the Framlngham (IBvpring Stud) (mean age 49 A 6 years) who were clinically free of coronary artery disease. After correction far sampling In hospital, hem-adrenerglc medication use and elects ofdiel,patientshad$gnlUnruly higher cholesterol levels (224 ± 53 vs . 214 ± 36 mgldl), triglycerides (189 ± 95 vs. 141 ± 104 mgld0, low density ipoprotee (LDL) cholesterol (156 t 51 vs . 138 3 33 mgldl), apolipoprote[n B (131 m 37 vs. 108 ± 33 agldl) and Lp(a) levels (19.9 *-t9 vs. 14.9 ± 17.5 mg/dl). They also had significantly lower high density lipoprotein (HDL) cholesterol (36 A 11 vs . 45 ± 12 mgldl) and apolipoprolein A-] levels (114 ± 26 vs . 136 4 32 mg'dl) (all p < 0.005).
On the basis of Lipid Research Clinic 91hh percentile values for triglyeerides and LIIL cholesterol and 10th percentile salons for HDL cholesterol, the most Eloquent dysip[dendas were low HDL The leading cause of morbidity and mortality in the United States is coronary artery disease and its sequelae. The identification of subjects at risk of developing coronary atherosclersis is an important public health issue-In addition to other risk factors, such as male gender, increasing age, hypertension, diabetes and a family history of premature coronary artery disease, elevated plasma law density lipoprotein (LDL) cholesterol and decreased high density .2%) and Lp(a) excess (15.8% vs . 10%) In patients versus control subjects, respectively (p < 0.05) . Stepwise diseriminant analysis Indicates that smoking, hypertension, decreased apollpoprateh A-I, Increased apollpoprotein B, increased Lp(a) and diabetes are all significant (p < 0.051 factors in descending order of importance in distinguishing patients with coronary artery disease from normal control sub jests.
Not applying a correction for hem-adrenergic blocking agents, sampling bias and diet effects leads to a serious underestimation of the prevalence of LDL abnormalities and an overestimation of HDL abnormalities in patients with coronary artery disease . However, 35% of patients had a found cholesterol level <200 mg/dl alter correction ; of (hose patients, 73% had an HDL cholesterol level <35 mg/dl, (J Am Call Curdiol 1992,19c792-802) lipoprotein (HDL) cholesterol have been shown to be independent predictors for coronary artery disease in prospective (I-11) and case-control (12-44) epidemiologic studies . In view of the muhifaelorial etiology of coronary atherosclerosis, no single biochemical variable will identify all patients at risk for developing coronary atherosclerosis . The effects of the various risk factors are clearly cumulative and the identification of mstjor biochemical markers and their interrelations should allow earlier detection of patients at risk (4, 45) . Elevated LDL cholesterol and decreased HDL cholesterol concentrations are associated with an increased risk of developing coronary artery disease 1). The major apolipoprotcins of LUL and HDL particles, namely, ape lipoprotein B and apolipoprotein A-1, respectively, are strongly associated with the presence of coronary artery disease. An increased level of LDL apolipopretein B has been associated with increased risk, as has a low level of apolipoprotein A-1 (13-33, [36] [37] [38] [39] [40] [41] 43, 44) . Lipoprotein (a) [Lp(a)], first identified by Berg (46) , has been shown to be increased in patients wish angiograplically documented coronary artery disease (47) (48) (49) (50) (51) (52) (53) . Lp(a) consists of one or more molecules of ape opretein(a ;linkedbyacysteinebondtothe apalipoprolein B moiety of LDL particle, . Recently (14.55) . the molecular structure and complementary DNA I'DNAI of apolipoprolein fal have been elucidated and have revealed considerable homology between the plasminogen and epalipoprotein (a) genes. Variant forms of apolipcitiowin in) differ in apparent molecular weight, in part because of varying numbers of kringle-like domains in the molecule 1561.
Our ability to measure lipoproteins, npolipoproteins and Lp(a) has been greatly refined in the past few years . These variables are used in many studies to provide an assessment of cardiovascular risk in a given population . Most of these variables, however, are closely interrelated and their measuronent may not improve our ability to predict risk. The present study was undertaken to deterrrune lipid, lipoprotein nod apolipoorotein concentrntinns and the prevalence of ahnorealitiea is li oprerein h--Qslemh apolipoproteins A-1 and B and Lgla) in men with premature coronary artery disease, we also corrected for confounding variables that affect lipid and hpoprotern levels, such as the effect of sampling in the hospital (57, 58) , the use of medication-especially beta-adrenergic blocking drugs (59-62)-and the role of dietary changes in am patients (631. We also studied the interrelations among the variables and determined the most discdminantva•i-.h!as'resenceof coronary artery disease.
Methods
Subjects studied. Patients In = 3211 underwent elective cardiac catheterization and coronary angiognaphy for the diagnosis and determination of the extent of coronary artery disease at the New England Medical Center Hospital . The referral base of the hospital includes Greater Boston and Eastern Massachusetts . All patients were white men <60 years of age (mean x SD 50 a 71 at the time of coronary angiography . All were studied between July 1985 and December 1987. Patients with acute myocardial infarction, surgery or trauma in the 6 weeks preceding admission were excluded . as were those taking lipid-lowering medications . Information on other risk factors-hypertension (defined as a history of high blood pressure _I%95 mm Hg . treated ur not), diabetes (history of diabetes or treatment with an oral hypoglycemic agent or insulin) and smoking ()t 10 cigarettes) day in the year preceding the procedure) . as well as medications (especially diuretic drugs . beta-adrenergic blocking agents and calcium channel blocking drugs)-wars noted by direct interview and review of the patient's medical chart .
The degree of coronary artery disease was determined by two independent cardiologists unaware of the patient's inclusion in the study. The presence of coronary artery disease . defined as >S11fo stenosis of a major coronary artery . was identified on multiple projections (>75fa cross-sectional area stenosis) . Patients with minimal disease (<509h steno sis) or with normal angwgrams (n = 25) were excluded from the analysis . The study protocol was reviewed and accepted (67.69) . Normal ranges forapulipoproteins A-I and B were determined in 3 .541 participolds (men and women) from the Framingham Offspring Study-Apnlipoprotein immunoassays were standadzed with use of purified apolipoproteins subjected to amino acid analysis . Lp(a) was determined by ELISA, with use ofa monoclonal anti-Lp(a) antibody with no cress-reactivity to plasminogen and a pulyclunal antibody directed at the apulipoprolein (a) portion of Lp(a) [Macro Lp(a), Tenlmu Corp.] . This assay was standardized with use of purified Lp(a), with the mass corresponding to the entire particle . Lpla) levels were determined in 760 male control subjects and 256 men with coronary artery disease ; lack of plasma samples accounts for the missing values . The 90th percentile far Lplal. based on the contra) group-was determined to be 39.8 mg dl . All apnlipoprotein and Lp(a) determinations were performed at the Lipid Metabolism Laboratory at Tufts University, Intm-and intermit coefficients ofvariance for these assays were <10%.
Did elfeets. We attempted to correct for a possible diet effect by analyzing the nutrient intake (as a percent of calories) in 43 wren with coronary artery disease and 96 Framingham control subjects by using feed frequency ques-tionnaires (69) . The coronary artery disease group had slightly lower total tat consumption than did the control group (29 .3% vs. 32.1%), with the following differences in saturated . monosaturated and polyunsaturated fats : 10 .2% vs . 12_9%; 11 .4% vs. 13 .3% and 8.6% vs. 5 .9%, respectively . The daily cholesterol intake was 105 vs . 150 mg1l,000 kenl . By applying the formula of Hegsted et al. (70) to determine the change in total cholesterol, patients with coronary artery disease would be expected to have a 6 .6% decrease in total cholesterol. On the basis of this subset analysis, we extrapolated the effects of diet to the coronary artery disease group and made the following assumptions: the effect of the diet was the same for all patients (that is, a decrease of 6 .6% in total cholesterol due to a decrease in LDL cholesterol), apofpes ro7e ;a B changed to the some degree as LDL cholesterol and there was no significant effect overall on .riglycedde HDL cholesterol apolipoprotein A-I or Lp(a) levels. Body mass index was calculated as weight (kg)l height'-(cm).
Statistical analysis, The data were stored on a VAX 111780 computer (Digital Equipment Corp .) with use of the database RS/1(BBN Software). The normality of continuous lipoprotein measures was tested by using the KolmogorovSmirnoff test . Triglycerides and Lpta) levels were transformed ey using log ln to better approximate a normal distributionThe group-, d est was used tocompare atient and control groups for these variables . Unpaired two-tailed r tests were used to evaluate the differences between mean values for variables having a parametric distribution . Log1o transformation of nonparametric variables was performed and the r test was then used . Chi-square analysis was used to evaluate the differences in smoking, diabetes, hypertension and use of heta-blockers, as well as differences in prevalence of lipid disorders . Multiple regression analyses were conducted by using the Statistical Analysis Software (SAS) package to determine correlation coefficients between the clinical data and lipid analyses . We corrected for noted beta-blocker effect, in-hospital sampling bias and diet effect and calculated the expected changes in lipid . lipoprotein cholesterol and apolipoprotein A-I and B levels . The Spearman correlation coefficients were used for variables not having a normal distribution . Stepwise discriminant analysis was performed by using a forward/backward procedure with hypertension, smoking, diabetes, triglycerides and lipoprotein cholesterol levels or apolipoprotein values entered into the statistical model .
Results
Clinical data (Table 11 . The mean age of the coronary artery disease and control groups was virtually identical, although a statistically significant difference was detected (50 ± 7 vs . 49 ± 6 years, patients vs . control subjects, p 0 .046) . The prevalence of hypertension was higher in the coronary artery disease group (41% vs . 20%. p < 0.001). as was the frequency of diabetes mellitus 1)2% vs . 3.2%, p < 0 .001) and smoking (67% vs . 28%, p < 0 .1811). Body mass index was 27 .79 ± 4 .08 in the coronary artery disease group versus 27 .14 ± 3 .66 in the control group (p = 0.024) . After correction for multiple t tests (Bonferroni correction), age and body mass index were no longer significantly difcrc^.t
Because of our previous finding (57) that sampling in patients in the hospital can lead to a bias in lipoprotein levels, especially for HDL cholesterol, we performed orospective resampiing in 72 patients after hospital discharge and ?6 weeks after cardiac catheterization. No significant effect on total . LDL and VLDL cholesterol, plas,na iriglycerides or apolipoprotein B concentrations was noted in the out of hospital state compared with the hospital sampling . However, as we have previously seen, HDL cholesterol and apolipoprotein A-I were lower at the time of the catheterizalion than in the out of hospital state (33 ± 9 vs . 37 ± 8 mg/dl, p<0 .001 and 105 ±23vs . 117 ±24mg/dl,is<0.001, respectively) . On the basis of this sample (58) and previously reported data (57) . we believed that a correction factor was necessary to compare HDL cholesterol and apolipoprotein A-1 values in the patient and control groups . The increase in HDL and apolipoprotein A-I concentrations observed out of hospital was proportional to the Initial (in-hospital) values, HDL cholesterol was thus increased by a factor of 1 .0916 and apolipoprotein A-I by 1 .101 for patients with coronary artery disease who underwent sampling in the hospital at the time of cardiac catheterization .
fedietsfion effect was also evaluated in patients with coronary artery disease ( Table 2 ) . Beta-blockers are known to exert an effect on plasma lipupreetein levels (59-62) . Of the 321 patients 113 (35%) were not and 206 (65%) were taking a beta-blocker. There were no statistically significant differences in total cholesterol or apolipoprotein B values in these two subgroups ; however, patients taking a betablocker had lower LDL cholesterol, HDL cholesterol and apolipoprotein A-I concentrations and higher triglyceride levels than did patients who were not taking such medication (p < 0 .05) ( Table 2 ) . Because the effects of beta-blockers on plasma lipoprotein concentrations are significant and twothirds of our patients were taking this class of medication, we analyzed the patients with coronary artery disease as a group, then separated those who were and were not receivir.2 hetis-btcaper rherap;. We ;!so 2 ;dsi21 triglyceride, LDL cholesterol, HDL cholesterol, apolipoprotein B and apolipoprotein A-I levels in patients taking a beta-blocker to those patient who were not taking a beta-blocker . We assumed that the differences observed between patients with artu without beta-blocker therapy were 7o!ely due to the use of such medication .
Lipid, lipoprotein and apolipoprotein levels (Tables 2 and  3 ) . To correct for a diet effect, total cholesterol, LDL cholesterol and apolipoprotein B towels were increased by 6.6%, as discussed . Uncorrected lipid, lipoprotein and aprlipoprotein levels are shown in Table 2 .
After adjustment for confounding variables, lipid and lipoprotein cholesterol and apolipoprotein levels in patients and control subjects were compared ( Table 3 ) . The patients with coronary artery disease had a 4.7% higher total choles- 0.001) . 16% lower apolipoprotein A-I l vt : f! 14 `_ 26 ys . 136 1-32 mgldl-p < 0 0011 . 25%p higher apolipnprolejn 8 level (131 ± 37 vs. 108 ± 33 mg/dl, p < 0.001) and 34% higher Lplal level (19 .9 ± 19 vs . 14 .9 s 17.5 mg/dl, p < 0.003). Not correcting for beta-blocker and diet effects significantly alters the classification of lipid disorders in patients with coronary artery disease on such medication ( Table 2) .
Prevalence of lipoprotein abnormalities (Table 4 ). The cut points used for lipoprotein abnormalities were the 90th percentiles for age and gender according to the Lipid Research Clinics data for total and LDL cholesterol and triglyceride levels and the 10th percentile for HDL choles-*As in Table 2 . trout cholesterol IT shot), law density lipoprotein ILDLI cholesterol, apolipoprotein A-1 (Apo A-I) and apolipoprotein b (Apo BI adjusI.d IADJ) for beta-edrerergic blacker use and effects ofdiet Iran rear). p' _ control subjects vs. patients with coronary artery disease after adjustment for beta-adreneBic biockers and diet effects . Abbreviations as in Table 2 I terol (71) . For apolipoproteins B and A-I, the values were derived from our control group of 901 men from the Framingham Heart Study free of clinical manifestations of coronary artery disease . The 90th percentile for apolipoprotein H and the 10th percentile roe apolipoprotein A-I were chosen as cut points. Based on a slightly smaller sample of control subjects (n = 760), the 90th percentile for Lp(a) was determined al 38.8 all The most frequeotr abnormality observed was ion, HDL cholesterol (hypoalphalipoproteinemia) after correction for hospital and medication effeots. The next most common phenotype was elevated LDL cholesterol either alone or in combination with elevated triglycerides or reduced HDL cholesterol. or both . The combination of hypertriglyeeri- demia and decrensed HDL cholesterol was also significantly higher in patients with coronary artery disease . The relation between hypertdglyceridemia and low HDL cholesterol has long been known (5) . The prevalence of elevated Lp(a) >38 .8 mgldl was higher in patients (15 .8%) than in control subjects (10%, p < 0 .05 ) . In the coronary artery disease group. four cases of heterozygous familial hypercholesterolemia with tendinous xanthomas were noted (estimated frequency 00125). In the control group, two patients had a cholesterol level >350 mg/dl with LDL cholesterol level 95th percentile . Based on the 90th percentile for triglycerides and LDL cholesterol and the 10th percentile for HDL cholesterol, 38.9% of patients had no abnormality compared with 73% of control subjects (p < 0 .001) ( Table 4) . A slightly higher proportion of patients had a significant lipid abnormality while taking a beta-blocker than while not taking such medication (64.4% vs . 57 .5%. data not shown) . The correlations among the lipid variables are shown in Table 5 .
The reinlina between LDL cholesterol and plasma apolipoprotein B on n scarrergram (data not shown) reveals that in some patients with coronary artery disease, elevation of apolipoprotein B occurs without a proportional elevation in LDL cholesterol . This observation has been previously made by Sniderman et al . (19) for LDL apolipoprotein B (72) and LDL cholesterol. The prevalence of elevated apolipoprotein B with normal LDL cholesterol (using the 90th percentile for both LDL and apolipoprotein B levels) was 19 .8% compared with 8 .4% in the control group (p < 0 .005) . However, only 10 .7% of the patients with coronary artery disease had elevated apolipoprotein B with normal (that is, <90th percentile) levels of triglycerides and LDL cholesterol. This provides an index of the frequency of hyperapobetalipoproteinemia (19) in this cohort .
Discriminant analysis (Table 6 ). Discriminant analysis reveals that conventional risk factors allow for an excellent discrimination between patients and control subjects (Table  6A) . When apolipoprotein variables were entered into the statistical model and triglycerides, total cholesterol, LDL cholestelvl and HDL cholesterol were removed, apolipoprotein B conferred better discrimination than did LDL choler . Based-lteccnao! subjects and 256 mar viv -11-y 1rry sory dill-. Abbrevietirv. a s T .64 2.
terol between patients and control subjects (Table 6B) .
Triglyceride concentrations appear to offer significant univariate discrimination between patients and control subjects, but were excluded from the made] with multivariate analysis. Mean and median Lp(al levels were higher in patients than in control subjects ; Lp(a) is an independent risk factor for the development of coronary artery disease . The second model that included traditional risk factors revealed that smoking, hypertension, apolipoprotein A-I, apolipoprotein R, Lp(a) and diabetes were all significantly associated with the presence of coronary artery disease . The frequency distributions for adjusted levels of LDL cholesterol (Fig. IA), apelipoprotein B (Fig. Ill) , HDL cholesterol (Fig . IC) , apolipoprotein A-1 (Fig . ID) , triglycerides (Fig. Ill) and Lp(a) (Fig . IF) are shown for patients and control subjects. Discussion identification of patients at risk for developing coronary artery direaax. This poses a daunting problem. Because of the nmhifactoriat etiology of the disorder in which environmental, genetic and nutritional aspects are so closely interrelated, it is becoming increasingly difficult to provide a cost-effective assessment of risk in the general population . The recently published recommendations of the National Cholesterol Education Program (45) have focused on total and LDL cholesterol as a basis for screening and treatment . Our data suggest that total and LDL cholesterol may not be the best discriminants for the presence of coronary artery disease despite the strong association between elevated cholesterol and the development of coronary artery disease in cross-sectional population studies and prospective epidemiologic studies. Although total cholesterol remains a good mariner for coronary artery disease between populations it,Z .20) . HDL cholesterol appears i0 be a better predictor within populations.
The present study shows that total and LDL cholesterol do not differ significantly between patients and control subjects it the confounding effects of diet and beta-blockers (73) are not taken into account, LDL cholesterol, however . is higher in patients not taking beta-Mockers than in control subjects and patients with coronary artery disease appear to have a healthier diet than normal control subjects .
Triglscerililm The association between triglyceride concentrations and coronary atherosclerosis deserves close scrutiny, We observed a significantly hig ;rer triglyceride cuacenlration in paliems with coronary artery disease than in control subjects, o' bserratiun previously noted (74, 75) , bat not in large, prospective epidemiologic studies . The negative coreclation between elevated triglycerides and decreased HDL cholesterol levels makes it difficult to consider triglyceride levels independently . B does appear that high triglyceride levels are associated with increased cardiovascular risk when they are associated with elevated levels of LDL cholesterol or plasma apotipoproteis B (type III, hyperlipoproteinemia or hyperapoheralipoproteinemia (761) or low HDL cholesterol levels, alone or in combination . Hyperlriglyceridemia alone, however, is not significantly more frequent in patients than control subjects, indicating that it is the combination of hypertriglyceridemia with elevated LDL or reduced H DL cholesterol . or both, that confers additional cardiovascular risk.
The data presented here show the importance of considering confounding variables, not only with respect to individual patients, but when interpreting epideutiologic studies dealing with lipids and coronary atherosclerosis . The high prevalence of dyslipldemias in the coronary artery disease group, irrespective of confounding variables, strongly supports the concept of the role or lipid disorders in the pathogenesis or coronary at erosclerosis . Diverse mechanisms will undoubtedly underlie must lipid disorders ; for the purpose of discussion, these disorders will be grouped into disorders of LDL, triglycerides, HDL and Lp(a).
Elevated LDL cislsled (type HA by i ). in this study, the prevalence of elevated LDL cholesterol in patients was 22.4% vs . 9,9% in control subjects (p < 0 .05) ( Table 4 ) after correction for confounding variables . If those variables are not taken into account, mean levels of LDL cholesterol and the prevalence of elevated LDL cholesterol are underestimated. The prevalence of elevated LDL cholesterol was 11,9% in patients before correction . The prevalence d LDL cholesterol >90th percentile without other abnormalities was 12 .3% vs . 9% in the control group. Heterozygems familial hypeecholesteenlemia (as defined by markedly elevated LDL cholesterol levels [>95th percentile], the presence of tendinouo xanthomas . familial segregation and premature coronary artery disease) was present in 4 of 321 patients (prevalence 0 .0125) . In the control group, two patients had total cholesterol levels >350 mgldl with LDL cholesterol >95th percentile (prevalence 0.002). Although Combined hyperllpidemia (types I® and IV hyperlipeprobinemias). The frequency of hypenriglyceridemia (without crude iipupratein abnormalities) was 9 .7% in the patient group versus 8 .5% (close to the expected frequency of 8 .1%) in the control group (p = NS) . Hypertriglyceridemia without elevated LDL cholesterol or decreased HDL cholesterol was not seen more frequently in patients with premature coronary artery disease in this study . The frequency of elevated triglycerides associated with low HDL cholesterol was higher than expected in the control group if both were independent of each other (which is not the case) . Hypertriglyceridemia combined with hypoelphalipoproteinemia is common in patients with coronary artery disease ( Table 4) . The frequency of elevated Iriglycerides and LDL cholesterol, with or without decreased HDL cholesterol, was greater in patients on a beta-blocker than those not taking such medication .
Hypoalphalipoprntelnemla (low HDI. ehokslerol). In the present study, the most common abnormality was hypoatphalipoproteinemia, cirheralane (19 .3% vs . 4.4%, p < 0 .001) or associated with an elevated triglyceride concentration (9 .7% vs . 4 .2%. patients vs . control subjects . p < 0.001). Bath the use of a beta-blacker and in-hospital sampling cause an overestimation of the prevalence of hypoalphalipaproteinemia, as does the higher proportion of smokers in our patient group (Table 1) . The frequency of "pure" hypoalphalipoproteinemia is lowerthan the expected level in the control group (4 .459) and the combined disorder of hypcetrigtyceridctrua with tow HDL cholesterol is higher than expected (4.2%). These observation underlie the close inverse association of triglycerides and HDL cholesterol. In the coronary artery disease group, 36.1% had low HDL cholesterol alone or in combination with other lipoprotein abnormalities compared with 9% in the control group-This represents a fourfold increase over values in control subjects. Ow data are consistent with previously published data . In several studies (14, 27, 35, 37, 40, 41, 43 ), the mean HDL cholesterol level :vas lower than reported in the present study . None of these studies has reported the prevalence of low HDL cholesterol in their patients based on the 10th percentile for age and gender . When considering the cut points of the National Cholesterol Education Program (45),35% (113 of 321) of our patients had a total cholesterol OENEST ET AL . No large population norms are as yet available for Lpial . In [his study Lp(a) levels were higher in the patient group than in the control group and a prevalence of Lpla) X38 .8 mgtdl was also higher in the coronary artery disease group . The frequency distribution of Lpla) is skewed to the right both in patients and in control subjects . The physiologic role of Lplat has not been elucidated, but Lp(m may interfere with i ntravascular thromholysis and inhibit the streptokinase-mediated mrroersic ; of plasmin from plasminogen . Furthermore, Lp(a) is found within atherosclerotic plaque and may contribute to cholesterol ester accumulation within the plaque (56) .
Apolipoprotein B. It has been suggested that apolipoprorein B and apolipoprotein A-I serve as better discriminators for the presence of coronary artery disease than LDL or HDL cholesterol . The level of apolipoprotein B was increased in our patients (Table 3 ) and the value was not influenced by sampling effect or beiablocker use . Furthermore, the frequency of elevated apolipoproteie B in the coronary artery disease group is nearly three times that in the control group after correction for confounders . Our assay does not measure LDL apolilactIptiotein B, but does measure total plasma apolipoprotein B . Therefore, we could not reliably establish the prevalence ofhyperapobetalipoproteinemia (elevated apolipoprotein B in LDL) as originally defined 019) in patients with coronary atherosclerosis because our assay for apolipoprotein B measures total plasma apolipnprntein B in comparison with the radial immunodiffusion (RID) assay that measures LDL apolipoprotein B (72) . However, in nermolipidemic patients (<90th percentile fur triglyeerides and LDL cholesterol), 1D .7% have an elevated apulipuprotein B alone compared with 4.5% in the control group. Apolipoprolein B nary reflect the number of apolipoprolein B-containing particles and thus provides betterdiscrinrfnation than the cholesterol content of VLDL and LDL particles .
Apolipuprotei Ad. Levels of apolipoprotein A-I were decreased in patients with coronary artery disease to a degree similar to the reduction in HDL cholesterol . The prevalence of low apolipopotein A-f (<10(h percentile) in patients was nearly 3 .5 times that found in control subjects (after correction for biases) . Comparing the two by stepwise discriminnnt analysis . apolipoprotein A-I appears slightly better than HDL cholesterol in differentiating patients from control subjects.
In this case-control study of 321 men with angiographically documented coronary artery disease, plasma levels of cholesterol, LDL cholesterol, triglycerides, apolipoprotein B and Lp(a) were increased and levels of HDL cholesterol ad apolipopratein A-I were decreased compared with a group of healthy middle-aged men with no clinical manifestations of coronary atherosclerosis. The prevalence of lipo-t3ENEST CT AL . LIPOPROTEINS IN CORONARY ARTERY DISEASE protein abnormalities was confounded by in-hospital sampling bias, dietary changes and use of beta-blockers . When these were taken into account, the most common abnormalities include hyimatphalipoproteinemia, combined hyper tiglyceridemia with hypoalphalipoproteinemia . elevated Lpla) and elevated L'DL cholesterol . The use of beta-blockers in patients results in overestimation of the frequency of hypertriglyceridemia and hypoalphalipoproteinumia and underesiimarion of the frequency of elevated LDL cholesterol .
Conclusions. This study revealed et high prevalence of dyslipidemias in patients with coronary artery disease . Clinical trials (79) (80) (81) (82) (83) have demonstrated that a reduction in elevated LDL cholesterol is associated with a reduction in cardiovascular mortality . The current guidelines of the National Cholesterol Education Program (45) are directed at the screening and treatment ofelevated LDL cholesterol levels . The prevalence of HDL cholesterol and triglyceride abnormalities Ives greater in the coronary artery disease group than in the control group and accounted for >51)% of the lipoprotein abnormalities identified in this study . We recommend that adult men with coronary artery disease hate a determination of HDL cholesterol, regardless of total cholesterol, and that healthy men have a determination of Higlycerides and HDL cholesterol if the total cholesterol is m200 mgldl. In addition, our data suggest that apolipoproteln 13, apolipoprotein A-I and Lp(a) are slightly better discriminators between patients and control subjects than am conventional lipoprotein variables .
To our knowledge, no other case-control studies in patients with coronary artery disease have taken into account the effects of sampling biases, medications and differences in diet compared with a control group, However, prospective studies have shown the importance ofelevated total and LDL chC:esterd in patients with coronary artery disease . Our study suggests that once these variables are taken into account, our results closely match those of prospective studies with regard to lipoproicin cholesterol levels. Moreover, the data point to the concept that in patients with established coronary artery disease more aggressive efforts should he made to lower LDL cholesterol levels to < 100 mg1dl and consideration should also be dueled to using agents known to raise HDL constituents (for -pee, macin, fenohbcate, gernlbrozil, 6ilnvasialin, tovastatin and pmvasatin).
